Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112226 · ClinicalTrials.gov registry record · NA
Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function
A NA study of Cognitive Impairment and Menopause, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT03112226: Completed NA study of Cognitive Impairment and Menopause, sponsored by University of Colorado, Denver.
NCT03112226 is a NA study of Cognitive Impairment and Menopause that has completed, run by University of Colorado, Denver. The registered enrollment target is 19 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03112226, a NA study of Cognitive Impairment and Menopause, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
Complaints about memory and thinking are common in women as they go through menopause. The female hormone estrogen is important for both the health of both the brain and the blood vessels. In Alzheimer's disease there is damage to the blood vessels in the brain. This study will look at how the loss of the female hormone estrogen affects brain function and the health of blood vessels.
Primary Outcome
Changes in patterns of brain activation in the prefrontal cortex using functional magnetic resonance imaging (fMRI) during a task of working memory will be measured at baseline and 3 months
Conditions Studied
Interventions
- OTHER GnRHant + E2
- OTHER GnRHant + Placebo
Study Locations (2)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- University of Colorado Boulder Intermountain Neuroimaging Consortium - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2020-06-21 |
| Phase | NA |
What the finished NCT03112226 record still lists
NCT03112226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which GnRHant + E2 is the first listed.
NCT03112226 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03112226 about?
NCT03112226 is a clinical study titled "Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function". Complaints about memory and thinking are common in women as they go through menopause. The female hormone estrogen is important for both the health of both the brain and the blood vessels. In Alzheimer's disease there is damage to the blood vessels in the brain. This study will look at how the loss ...
What is the current status of trial NCT03112226?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2018-02-07. Estimated completion is 2020-06-21.
What conditions does trial NCT03112226 study?
This clinical trial studies the following conditions: Cognitive Impairment, Menopause, Endothelial Dysfunction, Vascular Stiffness, Estrogen Deficiency.
What interventions are being tested in trial NCT03112226?
The interventions under investigation include: GnRHant + E2 (OTHER), GnRHant + Placebo (OTHER).
Who is sponsoring clinical trial NCT03112226?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03112226 being conducted?
This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03112226's enrollment target sits among peer trials
19 95th of 105 higher than 11 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI